Sara P C Paiva1, Clara A Veloso2, Fernanda F C Campos2, Márcia M Carneiro3, Jason U Tilan4, Hongkun Wang5, Jason G Umans6, Zofia Zukowska7, Joanna Kitlinska8. 1. Department of Physiology & Biophysics, Georgetown University Medical Center, Washington, DC, USA; Instituto de Ciências Biológicas e da Saúde, Centro Universitário de Belo Horizonte UNIBH, Belo Horizonte MG, Brazil; Hospital das Clínicas, Universidade Federal de Minas Gerais UFMG, Belo Horizonte Brazil. 2. Instituto de Ciências Biológicas e da Saúde, Centro Universitário de Belo Horizonte UNIBH, Belo Horizonte MG, Brazil. 3. Hospital das Clínicas, Universidade Federal de Minas Gerais UFMG, Belo Horizonte Brazil. 4. Department of Nursing, School of Nursing and Health Studies, Georgetown University, Washington, DC 20057, USA; Department of Human Science, School of Nursing and Health Studies, Georgetown University, Washington, DC 20057, USA. 5. Department of Biostatistics and Bioinformatics, Georgetown University Medical Center, Washington, DC, USA. 6. Department of Obstetrics and Gynecology, Georgetown University Medical Center, Washington, DC, USA; Department of Medicine, Georgetown University Medical Center, Washington, DC, USA. 7. Department of Physiology & Biophysics, Georgetown University Medical Center, Washington, DC, USA. 8. Department of Biochemistry and Molecular & Cellular Biology, Georgetown University Medical Center, Washington, DC, USA. Electronic address: jbk4@georgetown.edu.
Abstract
OBJECTIVE: To determine if preeclampsia (PE) is associated with dysregulation of the neuropeptide Y (NPY) system. METHODS: The study enrolled 114 subjects either with normal pregnancy (NP) or with PE. Systolic blood pressure (SBP) was collected from patients using a standard sphygmomanometer. The PE patients were divided into two groups based on the gestational age (GA) at delivery - placental PE (PLPE, GA <34 weeks) or maternal PE (MTPE, GA ≥34 weeks). NPY was measured in platelet rich plasma (PRP), platelet poor plasma (PPP) and in the serum of NP and PE patients utilizing radioimmunoassay. Serum levels of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) were measured in NP and PE subjects by ELISA. RESULTS: SBP was higher in PE compared to NP. Circulating NPY in serum and PRP, as well as NPY content per 100,000 platelets, but not its concentrations in PPP, were elevated in PE, as compared to NP. The highest NPY concentrations were observed in sera and PRP of patients with MTPE. PE patients had also elevated levels of sFlt-1, as compared to NP, although no difference between PLPE and MTPL groups were observed. There was no increase in P1GF in PE patients. CONCLUSION: Systemic NPY is elevated in PE patients, as compared to NP. This increase is observed in blood fractions containing platelets, suggesting accumulation of the peptide in these cells. NPY concentrations are particularly high in patients with MTPE, underlying differences in etiology between PLPE and MTPE. Our study implicates NPY as a potential target in antihypertensive therapies for PE patients.
OBJECTIVE: To determine if preeclampsia (PE) is associated with dysregulation of the neuropeptide Y (NPY) system. METHODS: The study enrolled 114 subjects either with normal pregnancy (NP) or with PE. Systolic blood pressure (SBP) was collected from patients using a standard sphygmomanometer. The PE patients were divided into two groups based on the gestational age (GA) at delivery - placental PE (PLPE, GA <34 weeks) or maternal PE (MTPE, GA ≥34 weeks). NPY was measured in platelet rich plasma (PRP), platelet poor plasma (PPP) and in the serum of NP and PE patients utilizing radioimmunoassay. Serum levels of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) were measured in NP and PE subjects by ELISA. RESULTS: SBP was higher in PE compared to NP. Circulating NPY in serum and PRP, as well as NPY content per 100,000 platelets, but not its concentrations in PPP, were elevated in PE, as compared to NP. The highest NPY concentrations were observed in sera and PRP of patients with MTPE. PE patients had also elevated levels of sFlt-1, as compared to NP, although no difference between PLPE and MTPL groups were observed. There was no increase in P1GF in PE patients. CONCLUSION: Systemic NPY is elevated in PE patients, as compared to NP. This increase is observed in blood fractions containing platelets, suggesting accumulation of the peptide in these cells. NPY concentrations are particularly high in patients with MTPE, underlying differences in etiology between PLPE and MTPE. Our study implicates NPY as a potential target in antihypertensive therapies for PE patients.
Authors: G J Hauser; M R Danchak; M P Colvin; R A Hopkins; B Wocial; A K Myers; Z Zukowska-Grojec Journal: Neuropeptides Date: 1996-04 Impact factor: 3.286
Authors: Bhavisha A Bakrania; Frank T Spradley; Heather A Drummond; Babbette LaMarca; Michael J Ryan; Joey P Granger Journal: Compr Physiol Date: 2020-12-09 Impact factor: 9.090
Authors: Cheryl M J Tan; Peregrine Green; Nidi Tapoulal; Adam J Lewandowski; Paul Leeson; Neil Herring Journal: Front Physiol Date: 2018-09-19 Impact factor: 4.566